Pulsesight
  • About us
    • About us
    • Team
    • Investors
  • Technology
  • Pipeline
    • Pipeline
    • About AMD
    • PST-611
    • PST-809
  • News & Events
    • Press Releases
    • Events
    • In the News
  • Contact

Category: In the news

EarlySight and PulseSight Therapeutics collaborate to add Cellularis® 2 Retinal Imaging to PST-611 Phase 2 Study

Posted on October 9, 2026October 12, 2026 by edgover
EarlySight and PulseSight Therapeutics collaborate to add Cellularis® 2 Retinal Imaging to PST-611 Phase 2 Study
Posted in In the news

PulseSight’s PST-611 Shows 35-52% Slowing of Retinal Cell Loss Biomarkers in Phase I Geographic Atrophy Trial

Posted on October 8, 2026October 19, 2026 by edgover
PulseSight’s PST-611 Shows 35-52% Slowing of Retinal Cell Loss Biomarkers in Phase I Geographic Atrophy Trial
Posted in In the news

New PST-611 Data Suggest Slower GA Progression

Posted on October 7, 2026October 19, 2026 by edgover
New PST-611 Data Suggest Slower GA Progression
Posted in In the news

PulseSight Reports Favorable Safety and Early Efficacy Signals for PST-611 in Geographic Atrophy

Posted on October 7, 2026October 20, 2026 by edgover
PulseSight Reports Favorable Safety and Early Efficacy Signals for PST-611 in Geographic Atrophy
Posted in In the news

RetinAI and PulseSight Therapeutics Expand Collaboration to Support Advancement of PST-611 Gene Therapy Program for Geographic Atrophy into Phase 2a

Posted on October 2, 2026October 12, 2026 by edgover
RetinAI and PulseSight Therapeutics Expand Collaboration to Support Advancement of PST-611 Gene Therapy Program for Geographic Atrophy into Phase 2a
Posted in In the news

Judith Greciet on Targeting Iron Dysregulation: PulseSight’s Next-Generation Approach to Geographic Atrophy

Posted on August 7, 2026August 7, 2026 by edgover
Judith Greciet on Targeting Iron Dysregulation: PulseSight’s Next-Generation Approach to Geographic Atrophy
Posted in In the news

PulseSight Therapeutics Reports P-I (PST-611-CT1) Trial Data on PST-611 in Dry AMD/Geographic Atrophy

Posted on May 11, 2026June 22, 2026 by edgover
PulseSight Therapeutics Reports P-I (PST-611-CT1) Trial Data on PST-611 in Dry AMD/Geographic Atrophy
Posted in In the news

PulseSight Reports Phase 1 GA Data

Posted on May 11, 2026June 22, 2026 by edgover
PulseSight Reports Phase 1 GA Data
Posted in In the news

PulseSight completes Phase 1 dosing of gene therapy candidate PST-611 in dry AMD and geographic atrophy

Posted on May 5, 2026June 22, 2026 by edgover
PulseSight completes Phase 1 dosing of gene therapy candidate PST-611 in dry AMD and geographic atrophy
Posted in In the news

PulseSight Completes Enrollment in Gene Therapy Trial

Posted on January 22, 2026January 23, 2026 by edgover
PulseSight Completes Enrollment in Gene Therapy Trial
Posted in In the news

Posts navigation

Older posts

Recent Posts

  • EarlySight and PulseSight Therapeutics collaborate to add Cellularis® 2 Retinal Imaging to PST-611 Phase 2 Study
  • PulseSight’s PST-611 Shows 35-52% Slowing of Retinal Cell Loss Biomarkers in Phase I Geographic Atrophy Trial
  • New PST-611 Data Suggest Slower GA Progression
  • PulseSight Reports Favorable Safety and Early Efficacy Signals for PST-611 in Geographic Atrophy
  • PulseSight presents PST-611 Phase I new early clinical efficacy data at EURETINA, offering a potential breakthrough approach to treat Dry AMD/Geographic Atrophy

Recent Comments

No comments to show.

Archives

  • October 2026
  • September 2026
  • August 2026
  • May 2026
  • April 2026
  • January 2026
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • February 2025
  • January 2025
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • April 2024
  • March 2024
  • February 2024

Categories

  • In the news
  • Press release
CONTACT US
PRIVACY POLICY
DISCLAIMER

© 2026 PULSESIGHT THERAPEUTICS ALL RIGHTS RESERVED